No licensed dosage has been established, as retatrutide has not yet received regulatory approval from the MHRA, EMA, or FDA
Not only has it demonstrated effectiveness in reducing cravings for binge eating disorders and other behaviors, but GLP-1s have also been praised for their ability to curtail one of the major downsides of antipsychotic medications: weight gain and other metabolic challenges for patients undergoing serious mental illness (SMI) treatment
The existing pattern across the GLP-1 class is that the weight-loss curve is driven hardest during titration and the first several months at target dose, and that once the primary loss is achieved, maintenance becomes a separate problem with a different tolerability budget
Back Mller, TD, Blher, M, Tschp, M, DiMarchi, iRD (2022) 'Anti-obesity drug discovery: advances and challenges', Nature Review Drug Discovery , 21, 201-23
Eli Lilly's Glp-1 Drugs Are Profitable, yet the Company Aims to Lower Patients' Out-of-pocket Costs Lilly Set Monjaro At $1,000, Reduced To $4.99/Month, Aiming For $100-300 Eli Lilly's success with GLP-1 drugs is evident in their profitability, underscored by significant revenue figures
Fat storage shifts from the hips and thighs toward the abdominal region
